Evidence map›Paper›PMID 42903206›Full record

ArticleFrontiers in immunology2026

NF-κB p65 iso5 Δ6/7 and p65 iso5 Δ10 isoforms drive immune-inflammatory remodeling in Fabry disease and

Giuseppa Biddeci, Paolo Colomba, Gaetano Spinelli, Monia Anania, Irene Giacalone, Giovanni Duro, Margherita Stefania Rodolico, Tommaso Silvano Aronica, Francesco Di Blasi

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giuseppa Biddeci *Institute for Biomedical Research and Innovation, National Research Council of Italy (CNR-IRIB), Palermo, Italy.
Paolo Colomba *Institute for Biomedical Research and Innovation, National Research Council of Italy (CNR-IRIB), Palermo, Italy.
Gaetano SpinelliInstitute for Biomedical Research and Innovation, National Research Council of Italy (CNR-IRIB), Palermo, Italy.
Monia AnaniaInstitute for Biomedical Research and Innovation, National Research Council of Italy (CNR-IRIB), Palermo, Italy.
Irene GiacaloneInstitute for Biomedical Research and Innovation, National Research Council of Italy (CNR-IRIB), Palermo, Italy.
Giovanni DuroInstitute for Biomedical Research and Innovation, National Research Council of Italy (CNR-IRIB), Palermo, Italy.
Margherita Stefania RodolicoInstitute for Biomedical Research and Innovation, National Research Council (CNR-IRIB), Section of Catania, Catania, Italy.
Tommaso Silvano AronicaComplex Operative Unit of Clinical Pathology, Azienda di Rilievo Nazionale ed Alta Specializzazione (ARNAS) Civico Di Cristina e Benfratelli Hospitals, Palermo, Italy.
Francesco Di BlasiInstitute for Biomedical Research and Innovation, National Research Council of Italy (CNR-IRIB), Palermo, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Fabry disease (FD) is an X-linked lysosomal storage disorder in which chronic inflammation contributes to disease progression beyond substrate accumulation. Although nuclear factor kappa B (NF-κB) signaling has been implicated in FD pathogenesis, the contribution of alternative NF-κB splicing to immune-inflammatory remodeling remains unknown. Here, we investigated the recently identified NF-κB p65 iso5 splice variants p65 iso5 Δ6/7 and p65 iso5 Δ10 in FD and in individuals carrying GLA variants of uncertain significance (GVUS). Methods: We characterized p65 iso5 Δ6/7 and p65 iso5 Δ10 in peripheral blood mononuclear cells from 103 patients with FD, including classic and late-onset phenotypes, 30 GVUS subjects, and 30 healthy controls. Isoform expression was assessed at the mRNA and protein levels, and circulating inflammatory mediators were evaluated in selected groups. Results: Both isoforms were constitutively expressed under physiological conditions and were significantly upregulated at the mRNA level in FD, whereas p65 iso5 Δ6/7 was also increased at the protein level. A similar expression profile was observed in GVUS subjects despite preserved α-galactosidase A activity and normal Lyso-Gb3 levels. In carriers of the p.Ala143Thr (A143T) variant, increased isoform expression was associated with enhanced expression of pro-inflammatory cytokines and elevated circulating inflammatory mediators. Discussion: Together with the previously reported downregulation of p65 iso5, these findings indicate that selective NF-κB splice variant redistribution, rather than uniform pathway activation, characterizes immune-inflammatory remodeling in FD. Altered p65 isoforms expression may contribute to immune dysregulation and clinical heterogeneity in FD and

Indexed as

alpha-GalactosidaseFabry DiseaseInflammationTranscription Factor RelAAdultAlternative SplicingFemaleHumansInflammation MediatorsLeukocytes, MononuclearMaleMiddle AgedProtein Isoformsalpha-GalactosidaseGLA protein, humanInflammation MediatorsProtein IsoformsRELA protein, humanTranscription Factor RelAalternative splicingFabry diseaseGLA variants of uncertain significanceimmune-inflammatory remodelinginflammatory signalingNF-κB isoformsp65 iso5 Δ10p65 iso5 Δ6/7

Identifiers

PMID42903206
PMCPMC13680232

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.